B
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Price:
5.8
PLN
1.67%
Market Cap:
zł378.5m
Balance Sheet
Balance Sheet Decomposition
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Balance Sheet Decomposition is not available for
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Balance Sheet
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Currency: PLN
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1
|
6
|
0
|
1
|
2
|
0
|
1
|
2
|
14
|
27
|
|
| Cash |
1
|
6
|
0
|
1
|
2
|
0
|
0
|
2
|
2
|
17
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
12
|
10
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
|
| Total Receivables |
6
|
0
|
11
|
9
|
7
|
7
|
5
|
11
|
12
|
15
|
|
| Accounts Receivables |
0
|
0
|
4
|
7
|
6
|
6
|
4
|
10
|
10
|
13
|
|
| Other Receivables |
6
|
0
|
7
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
|
| Inventory |
44
|
0
|
35
|
10
|
9
|
7
|
9
|
9
|
9
|
13
|
|
| Other Current Assets |
3
|
1
|
1
|
6
|
3
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Assets |
53
|
1
|
52
|
25
|
22
|
14
|
15
|
22
|
41
|
55
|
|
| PP&E Net |
38
|
0
|
83
|
99
|
72
|
57
|
53
|
51
|
63
|
97
|
|
| PP&E Gross |
38
|
0
|
83
|
99
|
72
|
57
|
53
|
51
|
63
|
97
|
|
| Accumulated Depreciation |
32
|
33
|
34
|
26
|
28
|
46
|
39
|
44
|
51
|
56
|
|
| Intangible Assets |
1
|
0
|
31
|
18
|
17
|
1
|
1
|
1
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
3
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
4
|
4
|
|
| Other Long-Term Assets |
3
|
0
|
5
|
13
|
9
|
11
|
9
|
9
|
8
|
6
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
97
N/A
|
0
N/A
|
172
N/A
|
156
-9%
|
121
-23%
|
86
-29%
|
81
-6%
|
86
+6%
|
117
+36%
|
163
+40%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
6
|
0
|
25
|
46
|
19
|
10
|
17
|
3
|
2
|
5
|
|
| Accrued Liabilities |
2
|
0
|
35
|
3
|
3
|
2
|
3
|
3
|
3
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
4
|
|
| Current Portion of Long-Term Debt |
4
|
0
|
12
|
19
|
3
|
10
|
1
|
6
|
3
|
3
|
|
| Other Current Liabilities |
4
|
0
|
41
|
0
|
1
|
0
|
0
|
11
|
8
|
9
|
|
| Total Current Liabilities |
17
|
0
|
113
|
69
|
26
|
22
|
20
|
25
|
17
|
24
|
|
| Long-Term Debt |
21
|
0
|
24
|
21
|
10
|
3
|
9
|
6
|
3
|
8
|
|
| Deferred Income Tax |
0
|
0
|
3
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Liabilities |
2
|
0
|
7
|
20
|
26
|
30
|
18
|
18
|
21
|
24
|
|
| Total Liabilities |
40
N/A
|
0
N/A
|
147
N/A
|
113
-23%
|
63
-44%
|
56
-12%
|
48
-14%
|
49
+1%
|
42
-13%
|
58
+36%
|
|
| Equity | |||||||||||
| Common Stock |
4
|
0
|
4
|
4
|
6
|
6
|
6
|
6
|
7
|
7
|
|
| Retained Earnings |
53
|
0
|
16
|
27
|
41
|
13
|
15
|
20
|
57
|
87
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
1
|
0
|
0
|
11
|
11
|
11
|
11
|
11
|
11
|
11
|
|
| Total Equity |
57
N/A
|
0
N/A
|
25
N/A
|
43
+75%
|
58
+34%
|
30
-47%
|
33
+8%
|
37
+14%
|
75
+100%
|
106
+42%
|
|
| Total Liabilities & Equity |
97
N/A
|
0
N/A
|
172
N/A
|
156
-9%
|
121
-23%
|
86
-29%
|
81
-6%
|
86
+6%
|
117
+36%
|
163
+40%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
39
|
0
|
44
|
44
|
57
|
62
|
62
|
62
|
65
|
70
|
|
Switch to:
Switch to:
See Also
Discover More
